Arc 1Sanqing’s Breakthrough
After discovering he had terminal cancer, Wei Kang used the Primary Pharmaceutical System to create a drug that cured cancer patients and brought Sanqing Pharmaceutical international attention. The arc ended with him weighing licensing offers and seeking multinational companies’ discarded drug formulas to fuel future discoveries.
- Wei Kang learned he had late-stage liver cancer as Sanqing Pharmaceutical faced heavy losses, then activated the Primary Pharmaceutical System and extracted a cancer-inhibiting effect from a failed drug formula.
- Wei Kang tested his new anti-cancer drug on himself, and doctors found that his cancer had sharply improved, and he arranged clinical trials with Jian Lianyun and Zhang Bo.
- Cao Jinmei livestreamed her rapid recovery during the trial, drawing public attention to Sanqing’s drug and prompting a surge of patients and media at the hospital.
- Wei Kang rejected Xinmei Group’s acquisition offer, raised funds for Sanqing, and announced the company’s anti-cancer and whitening products as the drug advanced through trials.
- At Sanqing’s launch conference, Wei Kang presented results showing a 100% response and cure rate among 420 patients, defended the data against Dr. Schmitz’s challenge, and attracted partnership offers from major pharmaceutical companies.
- Wei Kang refused to sell Sanqing or its drug formula and required potential partners to submit toxicity-tested abandoned drug formulas and side-effect data as part of their proposals.
- Wei Kang rejected Bayer’s acquisition offer and compared licensing proposals, favoring Pfizer’s terms while deciding to negotiate for its extensive catalog of abandoned drug formulas.